Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Federal Trade Commission
Dow
Fuji
McKinsey
Teva
Cantor Fitzgerald
Argus Health

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,753,265

« Back to Dashboard

Summary for Patent: 5,753,265
Title: Multiple unit pharmaceutical preparation
Abstract:A new pharmaceutical multiple unit tableted dosage form containing as active ingredient an acid labile H.sup.+ K.sup.+ -ATPase inhibitor or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, and the method of treatment with such a formulation in medicine.
Inventor(s): Bergstrand; Pontus John Arvid (Gothenburg, SE), Lovgren; Kurt Ingmar (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/464,774
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Compound; Process; Use;

Drugs Protected by US Patent 5,753,265

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,753,265

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9402431-2Jul 08, 1994
PCT Information
PCT FiledJune 07, 1995PCT Application Number:PCT/SE95/00678
PCT Publication Date:January 25, 1996PCT Publication Number: WO96/01624

International Patents Family Members for US Patent 5,753,265

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1152671 ➤ Try a Free Trial
Czech Republic 9600730 ➤ Try a Free Trial
Czech Republic 294380 ➤ Try a Free Trial
Czech Republic 9600731 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Johnson and Johnson
Julphar
Fuji
Moodys
Accenture
Teva
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.